Clinical Trial Update: A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa [Phase 3]

View source ↗

Summary

Phase 3 long-term treatment study of B-VEC for dystrophic epidermolysis bullosa has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dystrophic Epidermolysis Bullosa

Drugs mentioned

• B-VEC (null)

Snippet

Sponsor: Krystal Biotech, Inc. | Conditions: Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa | Phase 3 | Status: COMPLETED